YOYusuke Ono

Yusuke Ono

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yusuke Ono has a total of 71 co-authors. Here are the top co-authors by number of shared publications:

  • Noriyuki Tomiyama

    The Department of Diagnostic and Interventional Radiology, The University of Osaka Graduate School of Medicine, Suita, Japan

    7 shared publications
  • Hiroki Higashihara

    Department of High Precision Image-guided Percutaneous Intervention, Osaka University Graduate School of Medicine, Osaka, Japan

    6 shared publications
  • Hiroki Yano

    The Department of Diagnostic and Interventional Radiology, The University of Osaka Graduate School of Medicine, Suita, Japan

    5 shared publications
  • Hiroki Higashihara

    The Department of Diagnostic and Interventional Radiology, The University of Osaka Graduate School of Medicine, Suita, Japan

    4 shared publications
  • Kaishu Tanaka

    The Department of Diagnostic and Interventional Radiology, The University of Osaka Graduate School of Medicine, Suita, Japan

    4 shared publications
  • Noriyuki Tomiyama

    Department of Radiology, Osaka University Graduate School of Medicine, Suita, Japan

    4 shared publications

Latest Publications

  • Open Access

    Efficacy and safety of conventional transarterial chemoembolization for hepatocellular carcinoma using a glass membrane emulsification device: comparison with a three-way stopcock

    by Yusuke Ono, Yasushi Kimura, Yu Masuda, Hiroki Satomura, Kosuke Tomotake, Yuji Koretsune, Hiroki Yano, Daisuke Katayama, Kaishu Tanaka, Hiroki Higashihara, et al.

    Purpose: To compare the efficacy and safety of conventional transarterial chemoembolization (cTACE) using a glass membrane emulsification device (GMD) versus a three-way stopcock (3WS) in treatment-naïve target lesions of hepatocellular carcinoma (HCC). Materials and methods: We retrospectively analyzed 54 patients (73 target lesions) treated with GMD-cTACE and 39 patients (55 target lesions) treated with 3WS-cTACE. The emulsion consisted of 5 mL of Lipiodol and 2.5 mL of an iodinated nonionic contrast medium (iomeprol 300 mg I/mL) containing 50 mg of epirubicin. The primary endpoints were the direct treatment effect on target lesions, assessed by RECICL (2015). Recurrence-free survival (RFS), safety and modified albumin–bilirubin (mALBI) grade changes were evaluated as secondary endpoints. Results: TE4 rates were 86.3% in the GMD group and 76.4% in the 3WS group ( P = 0.15). The combined TE4 + TE3 rates were 93.2% versus 83.6%, respectively ( P = 0.09). The median RFS of target lesions was 1,047 days in the GMD group and 362 days in the 3WS group. RFS of target lesions tended to be longer with GMD (log-rank P = 0.058), with 1-year RFS estimates of 0.740 (GMD) and 0.470 (3WS). Restricted mean survival time (RMST) up to 365 days favored GMD (difference, 40.2 days; 95% CI, − 0.8 to 81.1; P = 0.054). Changes in hepatic reserve were not significantly different between groups. Conclusion: GMD-cTACE showed numerically longer RFS of target lesions than 3WS-cTACE, with no significant between-group difference in hepatic function deterioration. Standardizing emulsion quality with GMD may improve the durability of local control in cTACE; larger prospective studies are warranted.

  • Open Access

    Prospective Multicenter Observational Study of Silent Brain Infarction following Transradial Hepatic Intervention (The MOSAIC Study)

    by Yuji Koretsune, Miyuki Sone, Shintaro Kimura, Shunsuke Sugawara, Yoshihisa Kodama, Yasushi Kimura, Kaishu Tanaka, Yusuke Ono, Hiroki Higashihara, Yasuaki Arai, et al.


  • Open Access

    Efficacy of modified technique for 1 cm core needle biopsy using a 2 cm cutting length with coaxial introducer needle

    by Hiroki Satomura, Yasushi Kimura, Masahisa Nakamura, Kosuke Tomotake, Koki Yamamoto, Kaishu Tanaka, Yusuke Ono, Hiroki Higashihara, Noriyuki Tomiyama

    Purpose: This study evaluated the efficacy of a modified core needle biopsy using a 2 cm stroke length to improve tissue yield for molecular analyses in cancer genomics medicine. Methods: In vitro biopsy weight evaluations were performed using agarose gels of varying hardness. Ex vivo biopsy weight evaluations were conducted using chicken liver, gizzard, breast, and pork loin tissues. Furthermore, in vivo experiments were performed using murine subcutaneous tumor models. The modified method involved using a coaxial introducer needle to maintain a 1 cm notch length while employing a 2 cm stroke length to increase tissue yield. Biopsy performance parameters, including sample weight and DNA yield, were compared between the modified and conventional methods. The firing speed of the biopsy needles with 1 cm and 2 cm stroke lengths was also measured using a high-speed camera. Results: The modified technique significantly increased the sample volume across all agarose gel concentrations (9.5–13% increase, P < 0.05). Ex vivo tests revealed significantly higher tissue yields in most samples, except for chicken gizzards. In vivo, the modified method produced significantly larger tissue samples (4.6 mg vs. 2.9 mg, P < 0.001) and higher DNA yield (8.2 ng vs. 6.9 ng, P < 0.05). In addition, the biopsy needle’s firing speed was 1.4–1.8 times faster with the 2 cm stroke length than 1 cm stroke. Conclusion: The modified biopsy technique using a 2 cm stroke length significantly improved tissue yield, enhancing the quality of biopsy samples for molecular analyses in precision medicine.


  • Open Access

    Ethiodized Oil Emulsion for Sustained Release of Anti–PD-L1 Antibodies

    by Hiroki Satomura, Yasushi Kimura, Norifumi Kennoki, Kosuke Tomotake, Hiroki Yano, Yuji Koretsune, Daisuke Katayama, Kaishu Tanaka, Yusuke Ono, Hiroki Higashihara, et al.


  • Open Access

    Successful endovascular embolization of the common hepatic artery for pseudoaneurysm associated with pancreatic fistula after liver transplantation: a case report

    by Kazuki Sasaki, Tadafumi Asaoka, Shogo Kobayashi, Yoshifumi Iwagami, Daisaku Yamada, Yoshito Tomimaru, Takehiro Noda, Hiroshi Wada, Kunihito Gotoh, Hidenori Takahashi, et al.

    Background: After orthotopic liver transplantation (OLT), complications such as hepatic artery stenosis, thrombosis, and bleeding are possible. Hepatic artery pseudoaneurysms (HAP) are prone to rupture, rupture hemorrhage, and increased mortality risk. Endovascular treatment of HAP may result in recurrence, even after successful embolization with thrombin. Formation of a HAP in the common hepatic artery (CHA) is challenging because the CHA is the only artery in the liver graft after OLT. Therefore, CHA embolization in HAP is not an initial option. We report a case of HAP at the CHA after OLT that was treated with endovascular therapy, resulting in the occlusion of the CHA with coil embolization, achieving a radical cure. Case presentation: A 59-year-old man with decompensated hepatitis C virus cirrhosis underwent deceased donor whole-liver transplantation after graft failure of a living donor liver transplantation. After the second transplantation, the patient developed infectious narrow-necked HAP at the CHA associated with postoperative pancreatic fistula. Repeated transcatheter arterial embolization with thrombin and n-butyl-2-cyanoacrylate was unsuccessful, as confirmed by postprocedure angiography, which revealed recanalization and regrowth of the HAP. Eight months after the first transcatheter arterial embolization, the patient presented with a chief complaint of abdominal pain due to an enlarged HAP. Angiography of the superior mesenteric artery (SMA) revealed a collateral bypass around the bile duct from the SMA to the liver graft. Coil embolization of the HAP in the CHA completely occluded the HAP without complications. More than 2 years after coil embolization, the liver graft function test results remained within normal limits without HAP recurrence. Conclusions: HAP at the CHA after liver transplantation can be fatal if ruptured. Because the liver is a highly angiogenic organ, even if initial treatment is not successful, radical treatment to occlude the CHA with HAP is possible if sufficient collateral vessels are developed.

  • Open Access

    Percutaneous sclerotherapy with OK-432 for lymphocele after pelvic or para-aortic lymphadenectomy: preliminary results

    by Eiji Kashiwagi, Yusuke Ono, Hiroki Yano, Shinya Kosai, Keisuke Nagai, Kaishu Tanaka, Hiroki Higashihara, Noriyuki Tomiyama

    Background: Lymphoceles can result from disruption of lymphatic vessels after surgical procedures in areas with extensive lymphatic networks. Percutaneous catheter drainage with sclerotherapy can be performed for the treatment of lymphoceles. OK-432 has been used to treat benign cysts, such as lymphangioma and ranula. Therefore, we aimed to report the efficacy and safety of sclerotherapy using OK-432 for postoperative lymphoceles. This study retrospectively analyzed 16 patients who underwent sclerotherapy using OK-432 for postoperative pelvic and para-aortic lymphoceles between April 1, 2012, and March 31, 2020. All the patients underwent percutaneous drainage before sclerotherapy. The indications for sclerotherapy were persistent drainage tube output of greater than 50 mL per day and recurrent lymphoceles after percutaneous drainage. If less than 20 mL per day was drained after sclerotherapy, the tube was removed. When the drainage tube output did not decrease to less than 20 mL per day after the first sclerotherapy, the second sclerotherapy was performed 1 week later. Technical success was defined as the completion of drainage and sclerotherapy procedures. Clinical success was defined as the resolution of the patient’s symptoms resulting from lymphoceles without surgical intervention. This study also evaluated the complications of sclerotherapy and their progress after sclerotherapy. Results: The mean initial lymphocele size and drainage duration after sclerotherapy were 616 mL and 7.1 days, respectively. The technical success rate and clinical success rate were 100% and 93%, respectively. Thirteen patients were treated by one-session sclerotherapy and three patients were treated by two-session sclerotherapy. Minor complications (fever) were observed in eight patients (50%). A major complication (small bowel fistula) was observed in one patient (7%). No recurrence of lymphoceles was observed during the mean follow-up period of 17 months. Conclusion: Sclerotherapy with OK-432 is an effective therapeutic method for postoperative lymphoceles. Although most complications are minor, a small bowel fistula was observed in one patient.


  • Risk Factors Associated with Clinical Failure of Uterine Artery Embolization for Postpartum Hemorrhage

    by Shinya Kosai, Hiroki Higashihara, Hiroki Yano, Eiji Kashiwagi, Keisuke Nagai, Kaishu Tanaka, Yusuke Ono, Tatsuya Miyake, Noriyuki Tomiyama


  • Open Access

    Percutaneous Sclerotherapy with OK-432 for Lymphocele after Pelvic or Para-aortic Lymphadenectomy: Preliminary Results

    by Eiji Kashiwagi, Yusuke Ono, Hiroki Yano, Shinya Kosai, Keisuke Nagai, Kaisyu Tanaka, Daiki Higashihara, Noriyuki Tomiyama

    Background: Lymphoceles result from disruption of lymphatic vessels after pelvic and/or para-aortic lymphadenectomy. Percutaneous catheter drainage with sclerotherapy can be performed for the treatment of lymphoceles. OK-432 has been used to treat for benign cysts, such as lymphangioma and ranula. Therefore, we aimed to report the efficacy and safety of sclerotherapy using OK-432 for postoperative lymphoceles. This study retrospectively analyzed 16 patients who underwent sclerotherapy using OK-432 for postoperative pelvic and para-aortic lymphoceles between April 1, 2012, and March 31, 2020. All the patients underwent percutaneous drainage before sclerotherapy. The indications for sclerotherapy were persistent drainage tube output of greater than 50 mL per day and recurrent lymphoceles after percutaneous drainage. If less than 20 mL per day was drained after sclerotherapy, the tube was removed. When the drainage tube output did not decrease to less than 20 mL per day after the first sclerotherapy, the second OK-432 injection was performed 1 week later. Technical success was defined as the completion of drainage and sclerotherapy procedures. Clinical success was defined as the resolution of the patient’s symptoms resulting from lymphoceles without surgical intervention. This study also evaluated the complications of sclerotherapy and their progress after sclerotherapy.Results: The mean initial lymphocele size and drainage duration after sclerotherapy were 616 mL and 7.1 days, respectively. The technical success rate and clinical success rate were 100% and 93%, respectively. Three patients were treated by two-session sclerotherapy. Minor complications were observed in eight patients, who presented with fever. A major complication was observed in one patient, who presented with a small bowel fistula. No recurrence of lymphoceles was observed during the mean follow-up period of 17 months. Conclusion: Sclerotherapy with OK-432 is an effective therapeutic method for postoperative lymphoceles.

  • Open Access

    PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibro-adipose vascular anomaly (FAVA)

    by Yumiko Hori, Katsutoshi Hirose, Michio Ozeki, Kenji Hata, Daisuke Motooka, Shinichiro Tahara, Takahiro Matsui, Masaharu Kohara, Hiroki Higashihara, Yusuke Ono, et al.

    Background: Fibro-adipose vascular anomaly (FAVA) is a rare and new entity of vascular anomaly. Activating mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene were identified at a frequency of 62.5% in FAVA cases. The PIK3CA mutations excessively activate mammalian target of rapamycin (mTOR) pathway, which promotes angiogenesis and lymphangiogenesis, implying that PIK3CA mutations may act as drivers of FAVAs. This study investigated the correlations between PIK3CA mutational status, clinicopathological features and immunohistochemical expression of the mTOR pathway in a series of FAVA. Methods: We retrospectively evaluated the clinical and pathological findings of four FAVA cases. We performed next-generation sequencing (NGS) with a custom panel of genes associated with the mTOR pathway and genes responsible for other vascular anomalies; followed by direct sequencing and immunohistochemical analysis of the mTOR pathway. Results: Two PIK3CA-mutation cases and two PIK3CA-wild-type (wt) cases exhibited similar typical clinical features of FAVA. Histological analysis revealed venous malformation, lymphatic malformation, nerves containing enlarged abnormal vessels and fibrofatty tissue were observed regardless of PIK3CA mutational status. In contrast to clinical and histological findings, the immunohistochemical expression of activated AKT and mTOR that are upstream of the mTOR pathway was detected in abnormal vessels of PIK3CA-mutation cases but not in those of PIK3CA-wt cases. However, activated eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and ribosomal protein S6 kinase 1 (S6K1), both of which are downstream effectors of the mTOR pathway, were expressed in abnormal vessels of both PIK3CA-mutation and PIK3CA-wt cases. Furthermore, targeting NGS did not find any common genetic mutations involved in the mTOR pathway among PIK3CA-wt cases. Conclusions: There was no significant association between the presence of PIK3CA mutations and the clinicopathological features of FAVA, suggesting that the PIK3CA gene is not necessarily involved in the onset of FAVA. FAVAs lacking PIK3CA mutations may be caused by other gene mutations that activate 4EBP1 and S6K1.


  • Open Access

    Recent technical advances in conventional transarterial chemoembolization for hepatocellular carcinoma in Japan

    by Hiroki Higashihara, Yusuke Ono, Kaisyu Tanaka, Kosuke Tomotake, Noriyuki Tomiyama

    Hiroki Higashihara *, Yusuke Ono, Kaisyu Tanaka, Kosuke Tomotake, and Noriyuki Tomiyama. Int J Gastrointest Interv 2021;10:152-60. https://doi.org/10.18528/ijgii210042